Truist initiated coverage of Disc Medicine (IRON) with a Buy rating and $86 price target Disc Medicine is a compelling stock to own due to key value drivers that include lead de-risked asset, bitopertin in rare genetic disorder erythropoietic protoporphyria, potential blockbuster anemia agent, DISC-0974, and DISC-3405 in blood disorder polycythemia vera, the analyst tells investors in a research note. The firm sees significant upside potential by the second half of 2026 for accelerated approval of bito, and positive confirmatory data by early-27, and also thinks risk/reward for 0974 is favorable with large upside potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Buy Rating for Disc Medicine: DISC-0974’s Potential in Myelofibrosis-Related Anemia
- Disc Medicine Elects Nadim Ahmed as Director
- Disc Medicine appoints Ahmed to its Board of Directors
- 3 Best Stocks to Buy Now, 7/4/2025, According to Top Analysts
- Disc Medicine assumed with an Overweight at Morgan Stanley